[go: up one dir, main page]

WO2006027474A3 - Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet - Google Patents

Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet Download PDF

Info

Publication number
WO2006027474A3
WO2006027474A3 PCT/FR2005/002162 FR2005002162W WO2006027474A3 WO 2006027474 A3 WO2006027474 A3 WO 2006027474A3 FR 2005002162 W FR2005002162 W FR 2005002162W WO 2006027474 A3 WO2006027474 A3 WO 2006027474A3
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
affinity
preparation
respect
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2005/002162
Other languages
English (en)
Other versions
WO2006027474A2 (fr
Inventor
Gerald Guillaumet
Sabine Berteina-Raboin
Kazzouli Said El
Philippe Delagrange
Daniel-Henri Caignard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of WO2006027474A2 publication Critical patent/WO2006027474A2/fr
Publication of WO2006027474A3 publication Critical patent/WO2006027474A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule (I) : dans laquelle : - A représente un groupement -NHCOR1 ou -CONHR1 dans lesquels R1 est tel que défini dans la description, - R2 représente un groupement alkoxy, - R3 représente un groupement aryle, arylalkyle ou aroyle, et leur utilisation pour le traitement des pathologies liées au système mélatoninergique.
PCT/FR2005/002162 2004-08-31 2005-08-30 Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet Ceased WO2006027474A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409202A FR2874611B1 (fr) 2004-08-31 2004-08-31 Nouveaux derives d'imidazopyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR0409202 2004-08-31

Publications (2)

Publication Number Publication Date
WO2006027474A2 WO2006027474A2 (fr) 2006-03-16
WO2006027474A3 true WO2006027474A3 (fr) 2006-06-08

Family

ID=34947773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2005/002162 Ceased WO2006027474A2 (fr) 2004-08-31 2005-08-30 Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet

Country Status (3)

Country Link
AR (1) AR050542A1 (fr)
FR (1) FR2874611B1 (fr)
WO (1) WO2006027474A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273761B2 (en) 2006-12-08 2012-09-25 Takeda Pharmaceutical Company Limited Tricyclic compound and medical use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5160764B2 (ja) 2006-10-13 2013-03-13 全薬工業株式会社 特定の構造の複素環化合物を含む抗鬱剤、脳保護剤、アミロイドβ沈着抑制剤または老化抑制剤
MX2009013332A (es) 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
EP2072516A1 (fr) * 2007-12-21 2009-06-24 Santhera Pharmaceuticals (Schweiz) AG Dérivés d'imidazopyridine substitués en tant qu'antagonistes du récepteur de la mélanocortine-4

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050563A1 (fr) * 1980-10-22 1982-04-28 Synthelabo Dérivés d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique
EP0092458A2 (fr) * 1982-04-21 1983-10-26 Synthelabo Dérives d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique
EP0172096A1 (fr) * 1984-08-07 1986-02-19 Synthelabo Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
WO1989001472A1 (fr) * 1987-08-17 1989-02-23 Nelson Research & Development Co. Composes analogues de la melatonine
EP0527687A2 (fr) * 1991-08-13 1993-02-17 Adir Et Compagnie Nouveaux dérivés d'aryléthylamines, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO2002066478A1 (fr) * 2001-02-20 2002-08-29 Astrazeneca Ab Antagonistes de l'hormone de liberation de la gonadotropine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0050563A1 (fr) * 1980-10-22 1982-04-28 Synthelabo Dérivés d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique
EP0092458A2 (fr) * 1982-04-21 1983-10-26 Synthelabo Dérives d'imidazo(1,2-a)pyridine, leur préparation et leur application en thérapeutique
EP0172096A1 (fr) * 1984-08-07 1986-02-19 Synthelabo Dérivés d'acylaminométhyl-3 imidazo[1,2-a]pyridines, leur préparation et leur application en thérapeutique
WO1989001472A1 (fr) * 1987-08-17 1989-02-23 Nelson Research & Development Co. Composes analogues de la melatonine
EP0527687A2 (fr) * 1991-08-13 1993-02-17 Adir Et Compagnie Nouveaux dérivés d'aryléthylamines, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO2002066478A1 (fr) * 2001-02-20 2002-08-29 Astrazeneca Ab Antagonistes de l'hormone de liberation de la gonadotropine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TRAPANI G ET AL: "Synthesis and Binding Affinity of 2-Phenylimidazo[1,2-alpha]pyridine Derivatives for both Central and Peripheral Benzodiazepine Receptors. A New Series of High-Affinity and Selective Ligands for the Peripheral Type", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, 1997, pages 3109 - 3118, XP002900938, ISSN: 0022-2623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273761B2 (en) 2006-12-08 2012-09-25 Takeda Pharmaceutical Company Limited Tricyclic compound and medical use thereof

Also Published As

Publication number Publication date
FR2874611A1 (fr) 2006-03-03
AR050542A1 (es) 2006-11-01
FR2874611B1 (fr) 2006-11-17
WO2006027474A2 (fr) 2006-03-16

Similar Documents

Publication Publication Date Title
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d'utilisation
WO2004092135A3 (fr) Composes therapeutiques
NO20070336L (no) Indolderivater som histamin-reseptorantagonister
EP1679309A4 (fr) Medicament antistress et usage medical correspondant
WO2009013211A3 (fr) Nouveaux dérivés pyrazolés
WO2007090141A3 (fr) Composés chimiques
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
WO2006034093A3 (fr) Inhibiteurs de bace
WO2008006969A3 (fr) Nouveaux derives tetracycuques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004093800A3 (fr) Derives de thyronamine et analogues et des methodes d'utilisation de ces composes
GB0323204D0 (en) Organic compounds
WO2007020213A3 (fr) Derives de thiazolylpiperidines
WO2004092100A8 (fr) Derives d'indene utilises en tant qu'agents pharmaceutiques
WO2006010591A3 (fr) Derives de quinazoline
WO2008104473A3 (fr) Inhibiteurs de kinase et procédés d'utilisation de ces derniers
WO2007134149A3 (fr) Dérivés de 3,4-dihydro-2h-benzo[1,4]oxazine et thiazine en tant qu'inhibiteurs de cetp
WO2009056707A3 (fr) Dérivés de l'ind0l-2-0ne disubstitues en 3, leur preparation et leur application en thérapeutique
WO2006047415A3 (fr) Composes inhibiteurs du facteurs xa
EA200870224A1 (ru) Бензо[f]изоиндол-2-илфенильные производные уксусной кислоты в качестве агонистов рецепторов ep
WO2004063185A8 (fr) Thiophene carboxamides utilises en tant qu'inhibiteurs de l'enzyme ikk-2
WO2007104485A3 (fr) Composés imidazo[2,1-b]thiazole substitués et utilisation dans la fabrication de médicaments
WO2006027474A3 (fr) Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase